Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

Background Increasing evidence supports an extensive and complex genetic contribution to
PD. Previous genome‐wide association studies (GWAS) have shed light on the genetic …

Background There are currently no treatments that stop or slow the progression of Parkinson's
disease (PD). Case–control genome‐wide association studies have identified variants …

Importance Substantial genome-wide association study (GWAS) work in Parkinson disease (PD)
has led to the discovery of an increasing number of loci shown reliably to be associated …

Parkinson’s disease is a genetically complex disorder. Multiple genes have been shown to
contribute to the risk of Parkinson’s disease, and currently 90 independent risk variants have …

Importance Atypical parkinsonian syndromes (APS), including progressive supranuclear palsy
(PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), may be difficult …

Objectives To examine the influence of the glucocerebrosidase (GBA) mutation carrier state
on age at onset of Parkinson’s disease (PD), the motor phenotype and cognitive function at …

Dementia is one of the most debilitating aspects of Parkinson’s disease. There are no
validated biomarkers that can track Parkinson’s disease progression, nor accurately identify …

Background Human genetics research lacks diversity; over 80% of genome‐wide association
studies have been conducted on individuals of European ancestry. In addition to limiting …

We performed the largest genome-wide association study of PD to date, involving the
analysis of 7.8M SNPs in 37.7K cases, 18.6K UK Biobank proxy-cases, and 1.4M controls. We …